Related Experiment Video

Updated: Nov 3, 2025

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells
09:51

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Published on: June 30, 2023

1.2K

Microtubule-Associated Protein ATIP3, an Emerging Target for Personalized Medicine in Breast Cancer

Maria M Haykal1,2, Sylvie Rodrigues-Ferreira1,2,3, Clara Nahmias1,2

  • 1Institut Gustave Roussy, Université Paris-Saclay, Inserm U981, Biomarqueurs Prédictifs et Nouvelles Stratégies Thérapeutiques en Oncologie, 94800 Villejuif, France.

Cells
|June 2, 2021
PubMed

Insights

ATIP3, an anti-cancer protein, is down-regulated in breast cancer. Its levels predict patient survival and response to taxane chemotherapy, marking it as a potential biomarker for personalized medicine.

Area of Science:

  • Oncology
  • Molecular Biology
  • Precision Medicine

Background:

  • Breast cancer remains a leading cause of cancer death in women globally.
  • Accurate clinical and molecular tumor data are crucial for effective therapeutic strategies.
  • Precision medicine necessitates identifying reliable companion biomarkers for targeted therapies.

Purpose of the Study:

  • To review the role of the anti-cancer protein ATIP3 (A Kinase Anchor Protein 3) as a potential biomarker in breast cancer.
  • To highlight ATIP3's association with patient prognosis and response to taxane chemotherapy.
  • To explore ATIP3's potential as a companion biomarker for personalized breast cancer treatments.

Main Methods:

  • Literature review of recent studies on ATIP3 and its encoding gene MTUS1.
  • Analysis of ATIP3 expression levels in breast cancer tissues.
  • Evaluation of ATIP3 as a prognostic and predictive biomarker.

Main Results:

  • ATIP3 expression is significantly down-regulated in breast cancer.
  • Reduced ATIP3 levels correlate with poorer patient survival.
  • ATIP3 expression predicts breast tumor response to taxane-based chemotherapy.

Conclusions:

  • ATIP3 is an emerging anti-cancer protein with significant implications for breast cancer treatment.
  • ATIP3 serves as a valuable prognostic and predictive biomarker.
  • ATIP3 holds promise as a companion biomarker for personalized therapies in ATIP3-deficient breast cancers.
Keywords:
MTUS1breast cancerchemotherapymicrotubulepredictive biomarkerprognostic biomarkertargeted therapytaxanestumor suppressor

More Related Videos

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.2K
Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

7.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.4K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.3K
Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
3.1K